{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:37:31Z","timestamp":1761057451024},"reference-count":30,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2000,9,1]],"date-time":"2000-09-01T00:00:00Z","timestamp":967766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2000,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Sordarins are a new class of antifungal agents which selectively inhibit fungal protein synthesis (FPS) by impairing the function of elongation factor 2. The present study investigates possible correlations between sordarin pharmacokinetic (PK) properties and therapeutic efficacy, based on a murine model of invasive systemic candidiasis, and provides a rationale for dose selection in the first study of efficacy in humans. A significant correlation between PK parameters and the in vivo activity of GM 237354, taken as a representative FPS inhibitor, was demonstrated in a murine model of lethal systemic candidiasis. Area under the concentration-time curve (AUC) and maximum concentration of drug in serum (\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            ) over 24 h were determined after a single GM 237354 subcutaneous (s.c.) dose (50 mg\/kg of body weight) in healthy animals (no significant PK changes with infection were observed for other sordarin derivatives). These results have been used to simulate PK profiles obtained after several doses and\/or schedules in animal therapy. A PK-pharmacodynamic (PD) parameter such as the time that serum drug concentrations remain above the MIC (\n            <jats:italic>t<\/jats:italic>\n            &gt; MIC) was also determined. Treatment efficacies were evaluated in terms of the area under the survival time curve (AUSTC), using Kaplan-Meier survival analysis and in terms of kidney fungal burden (log CFU\/gram) after s.c. doses of 2.5, 5, 10, 20, and 40 mg\/kg every 4, 8, or 12 h (corresponding to total daily doses of 5 to 240 mg\/kg). The results show all treatments to significantly prolong survival versus that of infected and nontreated controls (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05). Relationships between simulated PK and PK-PD parameters and efficacy were explored. A good correlation independent of the dosing interval was observed with AUC (but not\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            or\n            <jats:italic>t<\/jats:italic>\n            &gt; MIC) and both AUSTC and kidney burden. Following repeated dosing every 8 h, AUC\n            <jats:sub>50<\/jats:sub>\n            (AUC at which 50% of the maximum therapeutic efficacy is obtained) was estimated as 21.7 and 37.1 \u03bcg \u00b7 h\/ml (total concentrations) for AUSTC and kidney burden using a sigmoid\n            <jats:italic>E<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            and an inhibitory sigmoid\n            <jats:italic>E<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            PK-PD model, respectively. For an efficacy target of 90% survival, AUC was predicted as 67 \u03bcg \u00b7 h\/ml. We conclude that the PK-PD approach is useful for evaluating relationships between PK parameters and efficacy in antifungal research. Moreover, the results obtained with this approach could be successfully applied to clinical studies.\n          <\/jats:p>","DOI":"10.1128\/aac.44.9.2333-2340.2000","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T09:56:57Z","timestamp":1027763817000},"page":"2333-2340","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":22,"title":["Pharmacokinetics-Pharmacodynamics of a Sordarin Derivative (GM 237354) in a Murine Model of Lethal Candidiasis"],"prefix":"10.1128","volume":"44","author":[{"given":"P.","family":"Aviles","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Glaxo Wellcome S.A., Parque Tecnolo\u0301gico de Madrid, 28760 Tres Cantos, Madrid, Spain,1and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Falcoz","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Glaxo Wellcome R&amp;D, Greenford, Middlesex, UB6 0HE, United Kingdom2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"San Roman","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Glaxo Wellcome S.A., Parque Tecnolo\u0301gico de Madrid, 28760 Tres Cantos, Madrid, Spain,1and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Gargallo-Viola","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Glaxo Wellcome S.A., Parque Tecnolo\u0301gico de Madrid, 28760 Tres Cantos, Madrid, Spain,1and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1258\/002367794781065870","article-title":"Guidelines for the welfare of animals in rodent protection tests. A report from the Rodent Test Working Party.","volume":"28","author":"Acred P.","year":"1994","unstructured":"Acred P. Hennessey T. D. MacArthur-Clark J. A. Merrikin D. J. Ryan D. M. Smulders H. C. Troke P. F. Wilson R. G. Straughan D. W. Guidelines for the welfare of animals in rodent protection tests. A report from the Rodent Test Working Party. Lab. Anim. 28 1994 13 18","journal-title":"Lab. Anim."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.2.384"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.9.2116"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF01062336","article-title":"Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics.","volume":"10","author":"Boxenbaum H.","year":"1982","unstructured":"Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharm. Biopharm. 10 1982 201 227","journal-title":"J. Pharm. Biopharm."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3109\/03602538308991421","article-title":"Evolutionary biology, animal behavior, fourth-dimensional space, and the raison d'\u00eatre of drug metabolism and pharmacokinetics.","volume":"14","author":"Boxenbaum H.","year":"1983","unstructured":"Boxenbaum H. Evolutionary biology, animal behavior, fourth-dimensional space, and the raison d'\u00eatre of drug metabolism and pharmacokinetics. Drug Metab. Rev. 14 1983 1057 1097","journal-title":"Drug Metab. Rev."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1995.tb04011.x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.1.64"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.9.2279"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.9.2274"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.3.289"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.7.1413"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.9.1905"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/infdis\/154.3.511","article-title":"Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect of 14 cephalosporins.","volume":"154","author":"Frimodt-Moller N.","year":"1986","unstructured":"Frimodt-Moller N. Bentzon M. W. Thomsen V. F. Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect of 14 cephalosporins. J. Infect. Dis. 154 1986 511 517","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/infdis\/147.5.910","article-title":"Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mouse.","volume":"147","author":"Gerber A. U.","year":"1983","unstructured":"Gerber A. U. Craig W. A. Brugger H. P. Feller C. Vastola A. P. Brandel J. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mouse. J. Infect. Dis. 147 1983 910 917","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.10.2197"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.2863"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.2042-7158.1997.tb06775.x","article-title":"Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species.","volume":"49","author":"Hutchaleelaha A.","year":"1997","unstructured":"Hutchaleelaha A. Chow H. H. Mayersohn M. Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. J. Pharm. Pharmacol. 49 1997 178 183","journal-title":"J. Pharm. Pharmacol."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/infdis\/159.2.281","article-title":"Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models.","volume":"159","author":"Leggett J. E.","year":"1989","unstructured":"Leggett J. E. Fantin B. Ebert S. Totsuka K. Vogelman B. Calame W. Mattie H. Graig W. A. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159 1989 281 292","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.5.1105"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/infdis\/162.3.717","article-title":"Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics.","volume":"162","author":"Mattie H.","year":"1990","unstructured":"Mattie H. van Dokkum A. M. Brus-Weijer L. Krul A. M. van Strijen E. Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics. J. Infect. Dis. 162 1990 717 722","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.4.733"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/38.1.5","article-title":"Is continuous infusion of beta-lactam antibiotics worthwhile?\u2014efficacy and pharmacokinetic considerations.","volume":"38","author":"Mouton J. W.","year":"1996","unstructured":"Mouton J. W. Vinks A. A. T. M. M. Is continuous infusion of beta-lactam antibiotics worthwhile?\u2014efficacy and pharmacokinetic considerations. J. Antimicrob. Chemother. 38 1996 5 15","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.14.1.6"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1128\/AAC.34.10.1932","article-title":"Comparative study of the effects of four cephalosporins against Escherichia coli in vitro and in vivo.","volume":"34","author":"Ogtrop M. L.","year":"1990","unstructured":"Ogtrop M. L. Mattie H. Guiot H. F. L. Strijen E. Hazekamp van Dokkum A. M. van Furth R. Comparative study of the effects of four cephalosporins against Escherichia coli in vitro and in vivo. Antimicrob. Agents Chemother. 34 1990 1932 1937","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF01967001","article-title":"Evaluation of quinolones in experimental animal models of infections.","volume":"10","author":"Scheld W. M.","year":"1991","unstructured":"Scheld W. M. Evaluation of quinolones in experimental animal models of infections. Eur. J. Clin. Microbiol. Infect. Dis. 10 1991 275 290","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_2_28_2","first-page":"1050","article-title":"Mathematical examination of dual individualization principles. I. Relationships between AUC above MIC and area under the inhibitory curve of cefmenoxime, ciprofloxacin, and tobramycin.","volume":"25","author":"Schentag J. J.","year":"1991","unstructured":"Schentag J. J. Nix D. E. Adelman M. H. Mathematical examination of dual individualization principles. I. Relationships between AUC above MIC and area under the inhibitory curve of cefmenoxime, ciprofloxacin, and tobramycin. DICP Ann. Pharmacother. 25 1991 1050","journal-title":"DICP Ann. Pharmacother."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.5.567"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.3.598"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.9.2030"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.9.2333-2340.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.9.2333-2340.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:47:09Z","timestamp":1645462029000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.44.9.2333-2340.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2000,9]]}},"alternative-id":["10.1128\/AAC.44.9.2333-2340.2000"],"URL":"https:\/\/doi.org\/10.1128\/aac.44.9.2333-2340.2000","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,9]]},"assertion":[{"value":"1999-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-06-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}